Volume 26, Number 2—February 2020
Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand
|Gene and mutation†||Amino acid change||No. patients with mutation
|Community patients||SHC patients||All patients||References|
|G285A||Met → Ile (95)||1||4||5||(1,9)|
||Met → Ile (95)
|C184T‡||Pro → Ser (61)||3||2||5||(1,9,11)|
|G241T||Gly → Cys (81)||1||0||1||(1,12)|
|A247C||Ser → Arg (83)||1||0||1||(1,3,9,12)|
|G248T||Ser → Ile (83)||2||6||8||(1–3,9)|
|T249A||Ser → Arg (83)||1||0||1|
|G259A||Asp → Asn (87)||2||0||2||(1–3,8,9,11)|
|G259T||Asp → Tyr (87)||2||3||5||(1,2,8,10)|
|C356T‡||Ala →Val (119)||1||0||1||(11)|
*Nucleotide position and amino acid changes shown are based on M. genitalium numbering. SHC, sexual health clinic.
†Silent mutations not reported.
‡Fluoroquinolone resistance not determined.
- Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. J Clin Microbiol. 2013;51:2245–9.
- Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24:822–8.
- Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol. 2017;55:3242–8.
- Yamaguchi Y, Takei M, Kishii R, Yasuda M, Deguchi T. Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium. Antimicrob Agents Chemother. 2013;57:1772–6.
- Basu I, Roberts SA, Bower JE, Henderson G, Reid M. High macrolide resistance in Mycoplasma genitalium strains causing infection in Auckland, New Zealand. J Clin Microbiol. 2017;55:2280–2.
- Kikuchi M, Ito S, Yasuda M, Tsuchiya T, Hatazaki K, Takanashi M, et al. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69:2376–82.
- Jensen JS, Björnelius E, Dohn B, Lidbrink P. Use of TaqMan 5′ nuclease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol. 2004;42:683–92.
- Deguchi T, Maeda S, Tamaki M, Yoshida T, Ishiko H, Ito M, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother. 2001;48:742–4.
- Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017;23:809–12.
- Shimada Y, Deguchi T, Nakane K, Masue T, Yasuda M, Yokoi S, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in parC associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2010;36:255–8.
- Hamasuna R, Le PT, Kutsuna S, Furubayashi K, Matsumoto M, Ohmagari N, et al. Mutations in parC and gyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS One. 2018;13:
- Dumke R, Thürmer A, Jacobs E. Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany. Diagn Microbiol Infect Dis. 2016;86:221–3.
- Golden MR, Workowski KA, Bolan G. Developing a Public Health Response to Mycoplasma genitalium. J Infect Dis. 2017;216(suppl_2):S420–6.
- Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, et al. Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis. 2018;24:328–35.
- Bébéar CM, Grau O, Charron A, Renaudin H, Gruson D, Bébéar C. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. Antimicrob Agents Chemother. 2000;44:2719–27.
Page created: January 20, 2020
Page updated: January 20, 2020
Page reviewed: January 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.